Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03894033

Post-market Registry of the AMDS for the Treatment of Acute DeBakey Type I Dissection

The objective of this registry is to collect information on the performance and clinical benefits of the AMDS (Ascyrus Medical Dissection Stent) to treat patients with acute "DeBakey type I dissections" and with or without so called "preoperative clinically relevant malperfusion" and/or "intramural hematomas".

In a healthy aorta (the vessel that supplies blood to most of the body) the blood flows freely through the main lumen (a space inside the vessel where blood flows). The participants involved in this study have a tear that has separated the inner layer of the aorta wall and created a secondary channel (false lumen) in addition to the main channel (true lumen), and huts, the blood flows through both channels.

AMDS is a stent (a metal tube helping to keep the vessel open) that is placed in the descending thoracic aorta. AMDS is a medical device commercially available in the countries in which the study is being conducted and it is used as standard of care according to its indication.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Deutsches Herzzentrum der Charité

Berlin, State of Berlin, 13353, Germany

About this study

Observational, prospective and retrospective, non-randomized, non-interventional study to investigate the performance and clinical benefits of the AMDS to treat patients with acute DeBakey type I dissections with or without clinically relevant preoperative malperfusion and/or intramural hematomas (IMH).

Participating physicians will be asked to provide their observations collected during routine care for patients they had decided to treat with AMDS. Informed consent of the patients to allow the use of their clinical records for the purpose of this observational study will be obtained before data are being collected.

A total number of 300 subjects will be enrolled in up to 30 sites in Europe and Canada. The AMDS will be implanted according to the instructions for use and at the discretion of the treating physician.

This registry was initiated by Ascyrus Medical GmbH in August 2019 (DARTS PM Registry). About 70 patients were enrolled at that time by German and Canadian sites under previous protocol. The patient's enrollment was put on-hold and the study has been re-started as PROTECT Registry with updated study documents as per JOTEC's standard operating procedures upon Ethics Committees approvals.

Patients already included in DARTS PM Registry will be re-consented (where applicable as per local regulatory requirements) to allow the retrospective and prospective collection of additional data points not included in the initial version of the protocol. It is also planned to retrospectively include up to 150 subjects of the 300 targeted subjects, which have been treated with AMDS and who consent to the collection of their data (if required by national law) and are willing to continue in this registry, if applicable.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥18 and ≤ 80 years of age (male or female)
  • One of the following diagnosed within 14 days:
  • Acute DeBakey type I dissection based on CT angiography; or
  • IMH based on CT angiography

Exclusion criteria

General Exclusion Criteria:

  • < 18 years of age or > 80 years of age (male or female)
  • Unwilling to comply with the follow-up schedule
  • Refusal to give Informed Consent

Medical Exclusion Criteria:

  • Uncontrolled systemic infection
  • Uncontrollable anaphylaxis to iodinated contrast
  • Known allergy(ies) to nitinol and/ or PTFE
  • Patient in extreme hemodynamic compromise requiring cardiopulmonary resuscitation (CPR)
  • Preoperative coma

Anatomical Exclusion Criteria:

  • Any pathology of mycotic origin
  • Subacute or chronic dissection of the ascending aorta and aortic arch (>14 days after the index event)
  • Aortic fistulous communication with non-vascular structure (e.g. esophagus, bronchial)
  • Extensive thrombus or calcification in the aortic arch as defined by CT angiography
  • Excessive tortuosity precluding safe passage of the AMDS as defined by CT angiography

Treatment and study plan

Ascyrus Medical Dissection Stent (AMDS)

Device

The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.

Other names: AMDS Arch Remodeling Therapy

Primary outcomes

  1. Positive arch remodeling

    Time frame: 3-6 months

    Rate of patients with positive arch remodeling defined as either stable or decreasing total aortic diameter in zone 2.

Secondary outcomes

  1. All-cause mortality

    Time frame: In-hospital, at 30 days, 3-6 months, 1 year, 2, 3, 4, 5 years

    Rate of all-cause mortality

  2. Device-related in-hospital mortality

    Time frame: Discharge (definition: between 1-29 days)

    Rate of device-related in-hospital mortality

  3. Device-related mortality

    Time frame: 30 days, 3-6 months, 1 year, 2, 3, 4, 5 years

    Rate of device-related mortality

  4. Resolution of malperfusion in patients who presented initially with malperfusion

    Time frame: Discharge (definition: between 1-29 days), 30 days, and 3-6 months

    Rate of patients with resolution of malperfusion in patients who presented initially with malperfusion

  5. New disabling (Modified Rankin Scale mRS ≥ 2), permanent (>30 days) stroke

    Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months,1 year, 2, 3, 4 and 5 years

    Rate of patients with new disabling (mRS ≥ 2), permanent (>30 days) stroke

  6. New disabling (Modified Rankin Scale mRS ≥ 2), transient (< 30 days) stroke

    Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months,1 year, 2, 3, 4 and 5 years

    Rate of patients with new disabling (mRS ≥ 2), transient (< 30 days) stroke

  7. New paralysis

    Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months,1 year, 2, 3, 4 and 5 years

    Rate of patients with new paralysis

  8. New paraplegia

    Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months, 1 year, 2, 3, 4 and 5 years

    Rate of patients with new paraplegia and 5 years

  9. New aortic rupture associated with the implantation of the device

    Time frame: 30 days, 3-6 months,1 year, 2, 3, 4 and 5 years

    Rate of patients with new aortic rupture associated with the implantation of the device (procedure or AMDS related)

  10. Patent innominate artery

    Time frame: Discharge (definition: between 1-29 days), 3-6 months,1 year, 2, 3, 4 and 5 years (CoreLab)

    Rate of patients with patent innominate artery (< 50% stenosis of the origin of the branch vessels)

  11. Source of innominate artery stenosis

    Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)

    Source of innominate artery stenosis (thrombosis, dissection flap covering, dissection extension into vessel)

  12. Patent left carotid artery

    Time frame: Discharge (definition: between 1-29 days), 3-6 months,1 year, 2, 3, 4 and 5 years (CoreLab)

    Rate of patients with patent left carotid artery (< 50% stenosis of the origin of the branch vessels)

  13. Source of left carotid artery stenosis

    Time frame: Discharge (definition: between 1-29 days), 3-6 months,1 year, 2, 3, 4 and 5 years (CoreLab)

    Source of left carotid artery stenosis (thrombosis, dissection flap covering, dissection extension into vessel)

  14. Patent left subclavian artery

    Time frame: Discharge (definition: between 1-29 days), 3-6 months,1 year, 2, 3, 4 and 5 years (CoreLab)

    Rate of patients with patent left subclavian artery (< 50% stenosis of the origin of the branch vessels)

  15. Source of left subclavian artery stenosis

    Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)

    Source of left subclavian artery stenosis (thrombosis, dissection flap covering, dissection extension into vessel)

  16. Absence of distal anastomotic new entry tear (DANE)

    Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4, and 5 years (CoreLab)

    Rate of patients with absence of distal anastomotic new entry tear (DANE)

  17. Increasing true lumen

    Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4, and 5 years (CoreLab)

    Rate of patients with increasing true lumen [change in diameter at the maximal diameter location within each Zone which is greater than or equal to a 5 mm expansion in comparison to the diameter on the pre-op computed tomography angiography (CTA) scan] in the stented region (Zones 1-3)

  18. Stable true lumen

    Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4, and 5 years (CoreLab)

    Rate of patients with stable true lumen [change in diameter at the maximal diameter location within each Zone which is between a 5 mm reduction and a 5 mm expansion in comparison to the diameter on the pre-op computed tomography angiography (CTA) scan] in the stented region (Zones 1-3)

  19. Stable or increasing true lumen in the stented region

    Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)

    Rate of patients with stable or increasing true lumen in the stented region (Zones 1-3)

  20. Decreasing true lumen

    Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)

    Rate of patients with decreasing true lumen [change in diameter at the maximal diameter location within each Zone which is greater than or equal to a 5 mm reduction in comparison to the diameter on the pre-op computed tomography angiography (CTA) scan] in the stented region (Zones 1-3)

  21. Increasing false lumen

    Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)

    Rate of patients with increasing false lumen (≥ 5mm) in the stented region (Zones 1-3)

  22. Stable false lumen in the stented region

    Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)

    Rate of patients with stable false lumen in the stented region (Zones 1-3)

  23. Decreasing false lumen

    Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)

    Rate of patients with decreasing false lumen (≤ - 5 mm) in the stented region (Zones 1-3)

  24. Rate of patients with stable or decreasing false lumen

    Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)

    Stable or decreasing false lumen in the stented region (Zones 1-3)

  25. Freedom from AMDS stent removal

    Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months, 1 year, 2, 3, 4 and 5 years

    Rate of patients with freedom from AMDS stent removal

  26. Freedom from AMDS-related reintervention

    Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months, 1 year, 2, 3, 4 and 5 years

    Rate of patients with freedom from AMDS-related reintervention

  27. Freedom from aortic arch reintervention

    Time frame: Discharge (definition: between 1-29 days), 30 days, 3-6 months, 1 year, 2, 3, 4 and 5 years

    Rate of patients with freedom from aortic arch reintervention

  28. Successful AMDS deployment (at discharge

    Time frame: Discharge (definition: between 1-29 days)

    Rate of patients with successful AMDS deployment (at discharge

  29. Completely thrombosed, partially thrombosed, or patent false lumen in the arch and descending aorta (Zones 0-5)

    Time frame: Discharge (definition: between 1-29 days), 3-6 months, 1 year, 2, 3, 4 and 5 years (CoreLab)

    Rate of patients with completely thrombosed, partially thrombosed, or patent false lumen in the arch and descending aorta (Zones 0-5)

Sponsors and collaborators

Lead sponsor

JOTEC GmbH

Industry

Registry information

Official study title

Post-market Registry of the AMDS for the Treatment of Acute DeBakey Type I Dissection: PROTECT Registry

Acronym: PROTECT

Important dates

Study start
2019
Primary completion
2026
Study completion
2030
First posted
Mar 28, 2019
Registry last updated
Feb 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.